Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE ...

Please provide your email address to receive an email when new articles are posted on . Between dose groups, there was no difference in the outcomes, including progression of hair loss. Patients ...

A new large-scale study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is just ...

A large-scale study provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is just as effective as conventional radiotherapy for prostate cancer, without ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

“Fully stocked on all things @higherdose and @hyperice , and I’m not mad about it,” Brown captioned the post. “From the red light neck mask to the sauna blanket, Normatec legs, and red ...

PITTSBURGH, March 17, 2025 (GLOBE NEWSWIRE) -- Recover Red, a leader in advanced wellness technology, has launched the PEMF+ Grounding Mat, a next-generation therapy device designed to ...